An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

Exclusion Criteria

• •Initiation or change of dosing (except for modifications to accommodate changes in weight or changes in standard of care) since completing a study administering SRP-5051 and while participating in this study for any of the following: angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blocking agents (ARBs), beta-blockers, potassium and steroids\*.
• •Requires antiarrhythmic and/or diuretic therapy for heart failure.
• •Use of any herbal medication/supplement containing aristolochic acid.
• •Treatment with any experimental therapy since entering original study or any experimental gene therapy for the treatment of DMD at any time.
• •Participation in an interventional clinical trial since completing original study.
• •\* The dose of steroids must remain constant except for modifications to accommodate changes in weight.